PD
ALXN

Planning Directions’s Alexion Pharmaceuticals ALXN Stock Holding History

Planning Directions’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,255
Closed -$202K – 106
2020
Q1 		$202K Buy
+2,255
New +$221K 0.28% 62

Other funds holding ALXN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Planning Directions's ALXN Position: Q2 2020 in Review

Planning Directions sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 2,255 shares — an estimated $202K sold.

Planning Directions first reported a position in ALXN in Q1 2020 and held it in 1 quarter. The position peaked at $202K in Q1 2020. 705 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

  • Planning Directions reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Planning Directions sold 2,255 Alexion Pharmaceuticals shares in Q2 2020, an estimated $202K.
  • Planning Directions first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Planning Directions's Alexion Pharmaceuticals position peaked at $202K in Q1 2020.
  • 705 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Planning Directions's 13F filing for Q2 2020, filed 21 Jul 2020.